Stockstowatch
About to take flight?I have been waiting for some of the most unloved parts of the market to pick up and that includes RTX and Aerospace. A decent reversal might be setting up if todays price action is any indication of what could come in the future. Stock is still well below highs in June and I think the outlook is better now then it was then. If we can hold this support zone and break above the trendlines the stock could be heading higher toward 76. Below 64 means the play is invalid.
Not investment advice
Reddit army buying heavily shorted REV stockShares of REV were jumping again as a massive short squeeze on consumer stocks continued into its third day.
The squeeze instigated by a group of traders on Gamestop has now spread to other heavily shorted stocks
There was no news out on any of these three stocks today, and certainly nothing of the kind that would generate this kind of movement for fundamental reasons.
Instead, traders on platforms like Reddit have figured out that they can take advantage of heavily shorted small-cap stocks if enough of them start buying them, and that's what's happened with REV stock.
When a stock is shorted and starts to go up, short-sellers eventually have to buy back the shares or risk further losses, including a margin call forcing the repurchase.
At Revlon, 31% of the stock's float was sold short as of the end of December.
www.fool.com
A massive short squeeze on PETSShares of PETS were jumping again as a massive short squeeze on consumer stocks continued into its third day.
The squeeze instigated by a group of traders on Gamestop has now spread to other heavily shorted stocks,
There was no news out on any of these three stocks today, and certainly nothing of the kind that would generate this kind of movement for fundamental reasons.
Instead, traders on platforms like Reddit have figured out that they can take advantage of heavily shorted small-cap stocks if enough of them start buying them, and that's what's happened with all three of these stocks. When a stock is shorted and starts to go up, short-sellers eventually have to buy back the shares or risk further losses, including a margin call forcing the repurchase.
Though only about 15% of the float is sold short, traders were aggressive to pump up the stock as daily trading volume rose as high as 358 million shares on Monday, up from around 3 million normally. As of midday today, volume had already topped 200 million.
PetMed Express, an online pet pharmacy, entered the new year with 41% of it stock sold short.
www.fool.com
Why GSX stock soared? Short-sellers are getting squeezed.......The coronavirus is getting worse in China, and it's possible that investors believe that's a good thing for GSX.
GSX is a remote-education company in China, and its business grew substantially in 2020. And if COVID-19 gets worse in that country, it's possible 2021 will be another good year for this business.
According to The Associated Press, new coronavirus cases are causing the Chinese government to lock down two hospitals in Shanghai.
it appears investors might expect GSX Techedu's services will be in greater demand if the pandemic worsens in China.
This is further complicated by short interest in this stock. According to Yahoo! Finance, around half of the stock's float was sold short up until recently. If investors are buying shares over the last few days because of the news coming out of China, it could be causing a short squeeze, as short-sellers are forced to cover their bearish positions.
Over 22% of GSX stock is sold short, giving it a short interest ratio of almost 14 days (anything over seven days is considered a lot). While that indicates short-sellers are getting squeezed, or being forced to cover their positions at ever-higher prices, it's more just a phenomenon flooding the market at the moment.
the company is under fire from many popular short-sellers, who claim GSX Techedu is a fraud.
And the company has indeed admitted that it is under investigation from the Securities and Exchange Commission (SEC). While that investigation is ongoing and it may turn out that everything is above board, this has caused a lot of people to actively bet against this stock.
The company faces the possibility of being delisted from major U.S. exchanges if the SEC finds wrongdoing. Therefore, it's important to approach a GSX Techedu investment fully aware of this risk.
Investors shouldn't be swayed by these price swings, and investors would be smart to sit on the sidelines until GSX Techedu sorts out the battle taking place between short-sellers and those long on its stock.
www.fool.com
Overstock to be limited partner in blockchain fundOverstock Partners with Pelion Venture Partners to Oversee Medici Ventures’ Blockchain Assets
Overstock to be limited partner in blockchain fund
OSTK today announces it will be converting Medici Ventures, Inc., its wholly owned blockchain-focused subsidiary, to a limited partnership (the “Fund”). An entity within Pelion Venture Partners, a third-party venture capital firm with a proven track record of successfully investing in early stage companies, will act as the general partner of the Fund.
Pelion has blockchain and technology expertise with early stage companies and has helped guide many companies to economic success.
Under the arrangement, which will close after obtaining necessary legal and regulatory approvals, Medici Ventures will be converted into a limited partnership.
finance.yahoo.com
Workhorse Rise on Biden EV PlanWorkhorse Rise on Biden EV Plan
WKHS rose on Tuesday, after President Joe Biden said in a speech that the U.S. government would be purchasing EVs.
"The federal government also owns an enormous fleet of vehicles, which we're going to replace with clean electric vehicles made right here in America, by American workers," Biden said.
Earnings PlayBuying stock and selling the 210 calls. Stop on the stock will be a close below 194. V has had a big sell off into earnings so I see potential for a relief rally back into the range.
Range ReversalBuying here with a stop on a close below 9.81. Target is 12 or higher. Oil has been strong as well as emerging markets so hopefully that will also be a catalyst besides the technical set-up
CVLB Expects 2020 Revenue up 205% to Record $38.0 MillionConversion Labs Expects 2020 Revenue up 205% to Record $38.0 Million, Subscription ARR up 525% to $26.0 Million
preliminary unaudited results for its fourth quarter and full year ended December 31, 2020.
Revenue for the fourth quarter is expected to total $13.6 million, up 265% from $3.7 million in the fourth quarter of 2019. Revenue for the full year is expected to total $38.0 million, up 205% from $12.5 million in 2019.
We ended the year exceptionally strong, with December revenues hitting a monthly record of $5.1 million, up 321% over December of last year. In fact, December 2020 alone eclipsed the whole of the fourth quarter of 2019.”
ual recurring revenue (ARR) generated by subscriptions reached $26.0 million by the end of the year, up 525% compared to the end of 2019 (see description of ARR, below). ARR increased by more than $3.0 million from November to December—another record-setting monthly gain.
“Given our extensive telehealth platform buildout in 2019, we were prepared when the breakout of the COVID-19 pandemic suddenly accelerated the consumer shift from traditional healthcare to telemedicine,”
expect 2021 to be our biggest year yet.”
finance.yahoo.com
Equity Investment and Strategic Business CooperationBaozun and iClick Announce Equity Investment and Strategic Business Cooperation
As a result of the agreement, Baozun will own 4% of iClick's shares outstanding and control 10% of its voting power.
The companies said they entered into a "strategic cooperation framework agreement" and will collaborate on a closed-loop e-commerce service model, focusing on areas like digital marketing, customer service, and fulfillment. That complements Baozun's core business of providing e-commerce services such as marketing, fulfillment, and IT for multinational companies like Microsoft and Nike. Also key in the deal is that both companies will develop a private domain traffic platform for Tencent, the tech giant and owner of the super-app WeChat.
A short squeeze may have also helped drive the shares higher.
Baozun is subject to a 180-day lock-up period on the above shares subscribed from iClick or purchased from the existing shareholder.
finance.yahoo.com
Pfizer forming a double bottom to continue moving up?Another update on PFE. Price has stalled for some time now around the internal support. We have a divergence with RSI and the price and RSI is starting to move above 50. MACD is making a bullish crossing and the histogram is going positive as well. Volumes are showing buying activity and we have a potential setup for a double bottom. Keep an eye on PFE.
Bank of America in risk of a trend reversalMy bearish view for Bank of America is almost confirmed. All is left is a move below $30.59 zone. RSI and MACD are flashing red and point for a continuation of the selling. Volumes are descending as activity is slowing down resent days.
Since the bad earnings, the bank is under pressure from investors, but still the downtrend is not entirely confirmed. Given the broader market and perpetual stimulus, BAC may have a second chance to continue its uptrend.
ASMB long term Buy EntryThe stock has outperformed and what I currently see Technically is strong upwards movements.
DYOR and if u like please hit the like button and subscribe for more updates.
EDSA to Study Investigational Drug as Potential Rescue TheraphyEdesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy
EDSA has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients. The sub-study will evaluate the drug as a potential rescue therapy for critically severe COVID-19 cases.
This sub-study will allow us to potentially expand the use of EB05 to critically ill patients suffering from profound, medically refractory COVID-19 respiratory failure," Dr. Nijhawan said.
finance.yahoo.com
Significant and Rapid Reduction in Hepatitis B Surface AntigenInitial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen
Data from the first blinded cohort of eight patients, two of whom received placebo and six of whom received a single dose of 6 mg of VIR-3434, showed that six of eight patients achieved a mean reduction of 1.3 log10 IU/mL in serum hepatitis B virus surface antigen (HBsAg) by day eight, the day when nadir was achieved in most patients.
Additional data will be submitted for presentation at an upcoming medical conference. A Phase 2 trial combining VIR-3434 with Vir’s HBV-targeting siRNA, VIR-2218, is expected to commence in the second half of this year.
finance.yahoo.com
operating income increase of 527%The company reported revenues of $191.7 million, net income of $10.9 million, and basic EPS (earnings per share) of $6.40. The company also reported operating income of $20.4 million, representing an increase of 527% over the same period last year. During the 2020 fiscal year, the company repurchased 236,908 shares of its common stock at an average price of $7.01 per share.
At September 30, 2020, the company reported total assets of $197.2 million and total liabilities of $153.5 million. Stockholders’ equity stood at $43.9 million, or $25.75 per basic common share1. At September 30, 2020, the company had cash and availability under its various lines of credit $37.7 million.
The Company completed two significant acquisitions in 2020, Lonesome Oak in January and Precision Marshall in July.
Trendline to watchAnother win for Wall St bets today! Not rooting against the crowd but yesterdays action should remind you how fast things can change. If you happen to be in the stock here is a trendline worth keeping an eye on so you have an idea when you can take some profits. Until then GME to the moon!
The Splunk doesn't smell anymoreSPLK was a range reversal trade that was underwater for most of the month but is now beginning to show signs of life. I have moved my stop to the most recent swing low at 159 and I am still looking for the stock to fill the gap (185-205). Rate of change is slightly positive which is encouraging. Still a while until earnings so no major planned news coming. Hoping the technical continue to point to higher prices
CymaBay Therapeutics $CBAY - investment idea 💡 ❌ - The volume is low on daily but increasing on 4h
✅ - We got double bottom on daily
✅ - We got Bullish engulfing action few days back on the lower channel at $5.64
✅ - MACD
✅ - STOCH
✅ - DeMarker
❌ - MA50 (13% under 50MA)
✅ - MA200 (6% above 200MA)
❌ - Pivots: (7% under the pivot point)
✅ - Ratings (7) buy
⏰ - Breakout 1: $6, Breakout 2: $6.40
🚀 - Potential targets (🚀+45%, 🚀🚀+81%, 🚀🚀🚀+107%)
🪂 - If things goes wrong better to exit under 5.62
🚦 - Next entries in case if dropped: $5.12, $4.20
⚠️ - This idea is based on my technical analysis only. Do your research and trade on your own risk!
--
Is CBAY A Good Stock To Buy Now?
finance.yahoo.com
CymaBay Therapeutics Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com
1.4 Million float with 42% short.$KOSS was the ultimate stock to feed to the Wall Street bets boys.
1.4 Million float with 42% short.
Like feeding a lamb to the lions.
twitter.com
43% of the float short on a 1.4 million float$KOSS has 43% of the float short on a 1.4 million float. That could be a Night mare for those short.
at-the-market offering for up to $35,000,000On January 25, 2021, IZEA Worldwide, Inc. (the “Company”) launched an at-the-market offering (the “Offering”) for up to $35,000,000 worth of shares of the Company’s common stock, par value $0.0001 per share, pursuant to an at the market (ATM) Sales Agreement, dated January 25, 2021, by and between the Company and National Securities Corporation. A copy of the ATM Sales Agreement is attached hereto as Exhibit 1.1 and is incorporated by reference herein.
The Company has 54,526,583 shares of common stock outstanding as of January 25, 2021.
Secondary stock offerings normally aren't a reason for shareholders to celebrate, but investors seem to see this one as a smart way for IZEA to raise cash it can use to fund additional growth efforts, as well as a validation of the stock's recent surge. The sale would dilute current shareholders by about 10%.
In 2019, the company's revenue declined 6% to $19 million and it lost $7.3 million.
If new products like Shake and its BrandGraph intelligence platform take off, the stock should have more room to run.
www.sec.gov
